Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy.

Früh- und Spättoxizitätsprofile bei Patienten mit unmittelbar postoperativer Radiotherapie vs. Salvage-Radiotherapie bei Prostatakarzinom nach Prostatektomie.

Journal

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 22 05 2018
accepted: 17 08 2018
pubmed: 6 9 2018
medline: 19 11 2019
entrez: 6 9 2018
Statut: ppublish

Résumé

The present study aims to evaluate both early and late toxicity profiles of patients receiving immediate postoperative radiotherapy (RT; adjuvant RT or additive RT) compared to salvage RT. We evaluated 253 patients with prostate cancer treated with either immediate postoperative (adjuvant RT, n = 42; additive RT, n = 39) or salvage RT (n = 137). Thirty-five patients received salvage treatment but did not achieve a postoperative prostate specific antigen (PSA) level <0.1 ng/ml and thus were excluded from analysis. A significantly higher rate of early grade 1/2 proctitis in the immediate postoperative RT group without additional pelvic RT was observed (p = 0.02). Patients in the immediate postoperative RT group without additional pelvic RT showed significantly more early urinary tract obstructions (p = 0.003). Toxicity rates of early (<3 months) and late (3-6 months) postoperative RT were similar (p > 0.05). Baseline recovery rate of erectile dysfunction was better in patients with immediate postoperative RT without additional pelvic RT (p = 0.02; hazard ratio (HR) = 2.22, 95%-confidence interval, 95%-CI: 1.12-4.37). Recovery rate of urinary incontinence showed no significant difference in all groups (p > 0.05). Patients receiving immediate postoperative RT (adjuvant or additive RT) without additional pelvic RT experience early gastrointestinal (GI) side effect proctitis and, as well as early genitourinary (GU) toxicity urinary tract obstruction more frequently than patients treated with salvage RT. Therefore, complete recovery after surgery is essential. However, we suggest basing the treatment decision on the patient's postoperative clinical condition and evaluation of any adverse risk factors, since many studies demonstrate a clear benefit for immediate postoperative RT (adjuvant or additive RT) in terms of oncological outcome.

Identifiants

pubmed: 30182246
doi: 10.1007/s00066-018-1359-2
pii: 10.1007/s00066-018-1359-2
doi:

Substances chimiques

Biomarkers, Tumor 0
Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

131-144

Références

BJU Int. 2000 Jul;86(2):181-90;quiz ii-iii
pubmed: 10886105
Lancet. 2005 Aug 13-19;366(9485):572-8
pubmed: 16099293
JAMA. 2006 Nov 15;296(19):2329-35
pubmed: 17105795
J Urol. 2007 Aug;178(2):529-34; discussion 534
pubmed: 17570425
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):115-25
pubmed: 19004572
J Urol. 2009 Mar;181(3):956-62
pubmed: 19167731
J Clin Oncol. 2009 Jun 20;27(18):2924-30
pubmed: 19433689
BJU Int. 2010 Dec;106(11):1618-22
pubmed: 20553253
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1316-22
pubmed: 20675081
Radiother Oncol. 2010 Dec;97(3):474-9
pubmed: 20950879
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):191-9
pubmed: 21109361
J Cancer Res Clin Oncol. 2013 Jan;139(1):147-57
pubmed: 22986810
Lancet. 2012 Dec 8;380(9858):2018-27
pubmed: 23084481
Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):822-8
pubmed: 23845839
Eur Urol. 2014 Jun;65(6):1034-43
pubmed: 23972524
Am J Clin Oncol. 2015 Feb;38(1):55-60
pubmed: 24051934
Strahlenther Onkol. 2014 Jun;190(6):569-74
pubmed: 24557057
Eur Urol. 2014 Aug;66(2):243-50
pubmed: 24680359
BJU Int. 2014 Mar;113 Suppl 2:7-12
pubmed: 24894850
Can Urol Assoc J. 2014 Jul;8(7-8):253-8
pubmed: 25210549
Strahlenther Onkol. 2015 Apr;191(4):375-9
pubmed: 25339311
Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94
pubmed: 25445556
PLoS One. 2015 Feb 23;10(2):e0118430
pubmed: 25706657
Asian Pac J Cancer Prev. 2015;16(14):5589-94
pubmed: 26320421
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Eur Urol. 2017 Jun;71(6):886-893
pubmed: 27484843
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Strahlenther Onkol. 2017 Jan;193(1):22-28
pubmed: 27632342
J Urol. 2017 Mar;197(3 Pt 1):669-675
pubmed: 27670915
Pract Radiat Oncol. 2017 Mar - Apr;7(2):e125-e133
pubmed: 28274403
Investig Clin Urol. 2017 May;58(3):152-163
pubmed: 28480340
Clin Transl Oncol. 2018 Feb;20(2):193-200
pubmed: 28667448
Strahlenther Onkol. 2018 Jan;194(1):23-30
pubmed: 28929310

Auteurs

Marco M E Vogel (MME)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Straße 22, 81675, Munich, Germany.
Institute for Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Neuherberg, Germany.

Kerstin A Kessel (KA)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Straße 22, 81675, Munich, Germany.
Institute for Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Neuherberg, Germany.
Partner Site Munich, Deutsches Konsortium für Translationale Krebsforschung (DKTK), Munich, Germany.

Jürgen E Gschwend (JE)

Department of Urology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.

Wilko Weichert (W)

Department of Pathology, Technical University of Munich (TUM), Munich, Germany.

Jan J Wilkens (JJ)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Straße 22, 81675, Munich, Germany.

Stephanie E Combs (SE)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Straße 22, 81675, Munich, Germany. stephanie.combs@tum.de.
Institute for Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Neuherberg, Germany. stephanie.combs@tum.de.
Partner Site Munich, Deutsches Konsortium für Translationale Krebsforschung (DKTK), Munich, Germany. stephanie.combs@tum.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH